Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 14Brain Neoplasms 12Glioma 11Astrocytoma 9Meningioma 7Central Nervous System Neoplasms 7Gliosarcoma 6Diffuse Intrinsic Pontine Glioma 6Recurrence 4Neurofibromatosis 2 4Tuberous Sclerosis 3Pheochromocytoma 3Paraganglioma 3Neuroma, Acoustic 3Rhabdomyosarcoma 2Oligodendroglioma 2Neurofibromatosis 1 2Neuroendocrine Tumors 2Neoplasms 2Hereditary Sensory and Autonomic Neuropathies 2von Hippel-Lindau Disease 1Zollinger-Ellison Syndrome 1Vestibulocochlear Nerve Diseases 1Tuberous Sclerosis 2 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Seizures 1Sarcoma 1Salivary Gland Neoplasms 1

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tuberous Sclerosis 2 × Everolimus × CNS × Clear all
NCT00790400 2017-02-17

EXIST-2

Novartis

Phase 3 Completed
118 enrolled 15 charts
CNS

Tuberous Sclerosis 2, Astrocytoma, Hereditary Sensory and Autonomic Neuropathies, Seizures, Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡